$Inhibikase Therapeutics (IKT.US)$Reuters 4 mins ago Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability! Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure
$ABVC BioPharma (ABVC.US)$- Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024. $Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
Report
AddiBee0925
:
Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Steve养老账户
:
I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
$Inhibikase Therapeutics (IKT.US)$ Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity Positive Secured significant financing of up to $275 million, including $110 million immediate private placement Received FDA Study May Proceed letter for IkT-001Pro PAH trial High trial completion rate with 120 of 126 patients completing the Phase 2 201 Trial Negative Increased net loss to $5.8 million in Q3 2024 from $4.6 million in Q3 2023 R&D expenses incr...
$Inhibikase Therapeutics (IKT.US)$ Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-SP IKT HOLDINGS LLC(8.69%),SP Soleus Holdings LLC(8.69%) Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Soleus Private Equity Fund III, L.P.(9.99%),Soleus Private Equity GP III, LLC(9.99%), etc.
$Inhibikase Therapeutics (IKT.US)$10.95 Million shares ((((. Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sands Capital Life Sciences Pulse Fund II, L.P.(16.3%),Sands Capital Ventures, LLC(16.3%), etc. SEC· Oct 25 17:52 )))
$Inhibikase Therapeutics (IKT.US)$ Inhibikase Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner Sands Capital Life Sciences Pulse Fund II, L.P.
$Inhibikase Therapeutics (IKT.US)$ Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sands Capital Life Sciences Pulse Fund II, L.P.(16.3%),Sands Capital Ventures, LLC(16.3%), etc.
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Inhibikase Therapeutics Stock Forum
Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth
4 mins ago
Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability!
Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Positive
Secured significant financing of up to $275 million, including $110 million immediate private placement
Received FDA Study May Proceed letter for IkT-001Pro PAH trial
High trial completion rate with 120 of 126 patients completing the Phase 2 201 Trial
Negative
Increased net loss to $5.8 million in Q3 2024 from $4.6 million in Q3 2023
R&D expenses incr...
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-SP IKT HOLDINGS LLC(8.69%),SP Soleus Holdings LLC(8.69%)
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Soleus Private Equity Fund III, L.P.(9.99%),Soleus Private Equity GP III, LLC(9.99%), etc.
SEC· Oct 25 17:52 )))
Inhibikase Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner Sands Capital Life Sciences Pulse Fund II, L.P.
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sands Capital Life Sciences Pulse Fund II, L.P.(16.3%),Sands Capital Ventures, LLC(16.3%), etc.
No comment yet